Johnson & Johnson (JNJ) Applied to the European Medicines Agency to Expand AKEEGA Usage

Johnson & Johnson (NYSE:JNJ) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 YearsOn July 3, Janssen-Cilag, a company of Johnson & Johnson (NYSE:JNJ), reported applying to the European Medicines Agency to expand the use of AKEEGA, a drug that combines niraparib and abiraterone acetate.

The new application seeks approval for treating adults with metastatic hormone-sensitive prostate cancer who have specific genetic changes called homologous recombination repair gene alterations. While treatments for mHSPC have improved, over 20% of mHSPC patients have HRR gene alterations, including the BRCA1/2 genes. These patients often have worse outcomes and limited treatment options.

Why JNJ Is a Long-Term Winner

A smiling baby with an array of baby care products in the foreground.

Janssen-Cilag’s submission is based on results from the Phase 3 AMPLITUDE study. This study tested niraparib and abiraterone acetate with prednisone or prednisolone versus the current standard treatment. The combination significantly delayed cancer progression and the worsening of symptoms.

Johnson & Johnson (NYSE:JNJ) is an international healthcare company that develops and sells medical products. The company operates through two main segments, which include Innovative Medicine and MedTech.

While we acknowledge the potential of JNJ to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.